These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15114068)

  • 21. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.
    Brandt J; Shearer B; Morgan SG
    J Pharm Policy Pract; 2018; 11():28. PubMed ID: 30443371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six Myths About Pharmacare.
    Lexchin J
    Health Law Can; 2017 Feb; 37(2-3):44-51. PubMed ID: 30005520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal prescription drug coverage in Canada: Long-promised yet undelivered.
    Morgan SG; Boothe K
    Healthc Manage Forum; 2016 Nov; 29(6):247-254. PubMed ID: 27744279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. It's Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada".
    Lexchin J
    Int J Health Policy Manag; 2020 Dec; 9(12):528-530. PubMed ID: 32610770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inter- and intraprovincial inequities in public coverage of cancer drug programs across Canada: a plea for the establishment of a pan-Canadian pharmacare program.
    Sorin M; Franco EL; Quesnel-Vallée A
    Curr Oncol; 2019 Aug; 26(4):266-269. PubMed ID: 31548806
    [No Abstract]   [Full Text] [Related]  

  • 27. Experience with providing drugs for seniors in Canada.
    Gray J
    Am J Geriatr Cardiol; 2005; 14(6):313-6. PubMed ID: 16276129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canadian pharmacare: looking back, looking forward.
    Morgan SG; Daw JR
    Healthc Policy; 2012 Aug; 8(1):14-23. PubMed ID: 23968600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment.
    Grootendorst P
    Can J Clin Pharmacol; 2002; 9(2):79-99. PubMed ID: 12172588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should national pharmacare apply a value-based insurance design?
    Yeung K; Morgan SG
    CMAJ; 2019 Jul; 191(29):E811-E815. PubMed ID: 31332049
    [No Abstract]   [Full Text] [Related]  

  • 31. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Hurley J; van Doorslaer E
    Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Children in need of Pharmacare: medication funding requests at the Toronto Hospital for Sick Children.
    Ungar WJ; Daniels C; McNeill T; Seyed M
    Can J Public Health; 2003; 94(2):121-6. PubMed ID: 12675168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do provincial drug benefit initiatives create an effective policy lab? The evidence from Canada.
    Pomey MP; Morgan S; Church J; Forest PG; Lavis JN; McIntosh T; Smith N; Petrela J; Martin E; Dobson S
    J Health Polit Policy Law; 2010 Oct; 35(5):705-42. PubMed ID: 21123668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disability in two health care systems: access, quality, satisfaction, and physician contacts among working-age Canadians and Americans with disabilities.
    Gulley SP; Altman BM
    Disabil Health J; 2008 Oct; 1(4):196-208. PubMed ID: 21122730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Home care, continuing care and medicare: a Canadian model or innovative models for Canadians?
    Béland F; Bergman H
    Healthc Pap; 2000; 1(4):38-45, discussion 109-12. PubMed ID: 12811171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recognize the role of employers.
    French M
    Healthc Pap; 2004; 4(3):46-50; discussion 68-72. PubMed ID: 15114069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-Adherence to Prescribed Therapies: Pharmacare's Existential Challenge.
    Gogovor A; Nemis-White J; Torr E; MacPherson N; Martin L; Aylen J; Manness LJ; Montague T
    Healthc Q; 2019 Jul; 22(2):21-26. PubMed ID: 31556375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards universal coverage: a policy analysis of the development of the National Health Insurance Scheme in Nigeria.
    Onoka CA; Hanson K; Hanefeld J
    Health Policy Plan; 2015 Nov; 30(9):1105-17. PubMed ID: 25339634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What can the Canadians and Americans learn from each other's health care systems?
    Weil TP
    Int J Health Plann Manage; 2016 Jul; 31(3):349-70. PubMed ID: 27469581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.